Introduction
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases worldwide, is the hepatic manifestation of metabolic syndrome and is strongly associated with obesity, dyslipidaemia, insulin resistance and type 2 diabetes (Byrne and Targher 2015) .
Steatosis is the primary factor responsible for the pathogenesis of NAFLD, which can progress to more advanced stages of liver disease, such as fibrosis, cirrhosis and even hepatocellular cancer (Rinella 2015) . Hepatic steatosis occurs because import or synthesis of fatty acids in hepatocytes exceeds export or catabolism (Rinella 2015) . It is well established that western dietary patterns, characterised by high intakes of fat and sugar, play an important role in the development of steatosis (Byrne and Targher 2015; Koch et al. 2015) . However, the mechanism contributing to high-fat diet (HFD)-induced steatosis has not been fully elucidated.
The Src family of kinases comprise nine non-receptor protein tyrosine kinases that share similar structure and function (Liu et al. 2013 ). Src, a ubiquitously expressed Src family kinase, is involved in many fundamental cellular processes, including proliferation, differentiation and inflammation (Liu et al. 2013) . More recently, a number of studies have highlighted the role of Src activation in the pathogenesis of various metabolic syndrome features, such as atherosclerosis (Chattopadhyay et al. 2015; Tao et al. 2015) and insulin resistance (Holzer et al. 2011) . However, the role of Src in hepatic steatosis and the mechanism underlying its effects remains to be investigated. Substantial evidence demonstrates that Src can be activated by oxidative stress (Pal et al. 2014; Chattopadhyay et al. 2015) . Additionally, it has been well demonstrated that oxidative stress is an important D r a f t 4 mediator of NAFLD aetiology and progression (Byrne and Targher 2015; Rinella 2015) .
Moreover, several studies have suggested that Fyn, an Src family kinase, is associated with the development of hepatic steatosis (Bastie et al. 2007; Fukunishi et al. 2011) . Based on these studies, we speculated that oxidative stress triggers Src activation, contributing to the development of HFD-induced NAFLD.
Currently, there is no approved pharmacological treatment for NAFLD, but natural products from plants, such as anthocyanin, exert beneficial effects on hepatic steatosis (Salomone et al. 2012; Xu et al. 2015) . Purple sweet potato color (PSPC), a class of naturally occurring anthocyanins, has a variety of biological activities such as antioxidant (Wu et al. 2015) , anti-inflammatory (Zhang et al. 2009; Wang et al. 2014) , hepato-protective (Zhang et al. 2009 ), antidiabetic (Lee et al. 2016) ,and anticancer effects. Previous work by our group has demonstrated that PSPC effectively attenuates hepatic insulin resistance and glucose metabolic dysfunction in HFD-treated mice (Zhang et al. 2013 ).
However, whether PSPC improves HFD-induced hepatic steatosis has never been investigated. Convincing experimental data have demonstrated that PSPC has strong antioxidant properties (Chao et al. 2014; Hu et al. 2016) . Therefore, we hypothesised that D r a f t 5 Institutional Animal Care and Use Committee of Jiangsu Normal University. Eight-week-old male ICR mice were purchased from Hua-fu-kang Biological Technology Co., Ltd (Beijing, China). Mice were housed at a temperature of 23°C±1°C and received food and drinking water ad libitum, with a relative humidity of 60% and a 12/12 h light/dark cycle (light from Brunswick, NJ, USA), daily oral administration of sterile distilled water containing the PSPC solvent; HFD+PSPC group: HFD diet, daily oral administration of PSPC at doses of 700 mg/kg/day in distilled water containing 0.1% Tween 80; PSPC group: normal diet, daily oral administration of PSPC at doses of 700 mg/kg/day in distilled water containing 0.1% Tween 80. PSPC were purchased from Qingdao Pengyuan Natural Pigment Research Institute (Qingdao, China). The major components of PSPC by HPLC analysis are cyanidin acyl glucosides and peonidin acyl glucosides (>90%, peonidin
and the rest is other flavonoids), as described in our previous work (Lu et al. 2012) .The dosage of PSPC used in this study was based on our previous work (Zhang et al. 2013 ) and our pilot study.
Eighteen weeks after HFD feeding, some mice from the HFD group were divided into two subgroups. The ERK1/2 inhibitor U0126 (Selleck Chemicals, Houston, TX, USA), was solubilised in phosphate buffered saline (PBS) containing 5% dimethyl sulfoxide (DMSO), was administered to one subgroup (HFD + U0126 group) for two weeks by daily intraperitoneal (i.p.) injections at a dosage of 20 mg/kg/day, and another subgroup (HFD-control group) received daily i.p. injections of an equal volume of vehicle.
Food intake was measured every 3 days. The body weights of mice were measured weekly.
After 20 weeks of treatment, the mice were deeply anaesthetised and sacrificed, and the blood, liver and epididymal fat were immediately collected for experiments or stored at -70 °C for later use.
Liver slice collection and histopathological analysis
Liver slice collection and histopathological analyses were performed as described in our previous work (Zhang et al. 2010) . The mice were transcardially perfused with 100 ml of 0.9% sterile saline. The liver tissues were fixed in a fresh solution of 4% paraformaldehyde (PH 7.4) at 4℃ for 24 h, then incubated overnight at 4℃ in 100 mmol/L sodium phosphate buffers (PH 7.4) containing 30% sucrose and embedded in optimal cutting temperature (OCT) compound (Leica, CA, Germany). The cryosections were collected on 3-animopropyl-trimethoxysilane-coated slides (Sigma-Aldrich, St. Louis, MO, USA) and D r a f t 7 stored at −70°C.
The liver slices were stained with haematoxylin and eosin (H&E, Sigma-Aldrich, St. Louis, MO, USA), and examined by an expert in liver pathology blinded to the type of treatment received by the animals. Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) staining was performed on 8-µm sections that were cut from frozen OCT samples, mounted on slides, and allowed to air-dry for 30 to 60 minutes at room temperature. The sections were fixed in ice-cold 10% formalin for 10 minutes and stained with Oil Red O for 10 minutes. The sections were then counterstained with Mayer's haematoxylin for 1 minute and rinsed in distilled water.
Tissue homogenates
Tissue homogenates were prepared for biochemical studies and western blot analysis as described in our previous work (Zhang et al. 2013) . For biochemical studies, the liver was promptly dissected and homogenized 1:10 (w/v) in 50 mmol/L (pH 7.4) ice-cold Tris-buffered saline containing a protease inhibitor cocktail using a Teflon-glass Potter-Elvehjem homogenizer for 10 strokes at 1200 rpm (Kontes, Vineland, NJ, USA).
Homogenates were centrifuged at 12 000 g for 10 min, and the supernatant was used to determine reactive oxygen species (ROS) levels, thiobarbituric acid reactive species(TBARS) levels, glutathione(GSH) levels and enzymes activities. For western blot analysis , the liver was homogenized 1:5 (w/v) in ice-cold RIPA lysis buffer (1 × Tris-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 0.004% sodium azide) supplemented with 30 µl 10 mg/ml phenylmethanesulfonyl fluoride (PMSF), 30 µl sodium orthovanadate (Na 3 VO 4 ) and 30 µl protease inhibitor cocktail per gram of tissue. The D r a f t 8 homogenates were sonicated 4 times for 30 s with 20 s intervals using a sonicator, centrifuged at 15 000 g for 10 min at 4°C, then the supernatant was collected and stored at -70 °C for western blot studies. Supernatant protein levels were determined using the bicinchoninic acid assay kit (Pierce Biotechnology, Rockford, IL, USA).
Biochemical analysis
The serum level of aminotransferase (ALT) was measured spectrophotometrically using 
Reactive oxygen species (ROS) assay
ROS was measured based on the oxidation of 2', 7'-dichlorodihydrofluorescein diacetate (H2-DCF-DA) to 2', 7'-dichlorofluorescein (DCF) as described in our previous work (Zhang et al. 2013) 
Measurement of lipid peroxidation level
The level of TBARS in liver tissue homogenates was determined as described previously (Zhang et al. 2009 ). Half a millilitre of each homogenate was mixed with 3 ml of H 3 PO 4 solution (1%, v/v) followed by addition of 1 ml of thiobarbituric acid solution (0.67%, w/v).
The mixture was incubated at 95 °C in a water bath for 45 minutes. The coloured complex was extracted into n-butanol, and the absorption at 532 nm was measured using tetramethoxypropane as standard. The TBARS levels were expressed as nmol per milligram of protein.
Glutathione (GSH) assays
The levels of GSH in the hepatic supernatants were determined according to the protocols D r a f t 10 of a commercially available GSH assay kit (Cayman Chemical, Ann Arbor, MI, USA). After reaction with 5, 5-dithiobes-(2-ni-trobenzoic acid) (DTNB), the GSH levels were determined at 405 nm with a spectrophotometer (Shimadzu UV-2501 PC, Shimadzu Corporation, Japan).
The results are expressed as the contents (µmol GSH) per mg of protein.
Glutathione peroxidase (GPx) activity assay
The GPx activity assay was performed as described in our previous work (Zhang et al. 2013 ). Tert-butylhydroperoxide was used as the substrate. The assay measures the enzymatic reduction of H 2 O 2 by GPx through consumption of reduced GSH that is restored from oxidised glutathione disulfide (GSSG) in a coupled enzymatic reaction by glutathione reductase (GR). GR reduces GSSG to GSH using NADPH as a reducing agent. The decrease in absorbance at 340 nm due to NADPH consumption was measured in a Molecular Devices M2 plate reader (Molecular Devices Corporation, Menlo. Park, CA, USA). GPx activity was computed using the molar extinction coefficient of 6.22 mM −1 cm −1
. One unit of GPx was defined as the amount of enzyme that catalysed the oxidation of 1.0 µmol of NADPH to NADP + per minute at 25 °C.
Kinase Activity Assay
Hepatic supernatants containing equivalent amounts of protein (500µg) were precleared using protein A-sepharose beads for 1 h at 4 °C followed by incubation with 1.5 µg anti-Src 
Western blot analysis
Western blot analyses were performed as described in our previous work (Zhang et al. 2013 ). Briefly, samples (50 µg protein) were separated on denaturing SDS-PAGE gels and The OD values were normalised using appropriate internal controls (optical density detected protein /optical density internal control ).
Statistical analysis
All statistical analyses was performed using SPSS version 11.5. All the data were analysed with a one-way analysis of variance (ANOVA) followed by Tukey's Honestly Significant Difference (HSD) post-hoc test. Data were expressed as means ± standard deviation (SD).
Statistical significance was set at p<0.05.
Results

PSPC attenuates obesity and related metabolic parameters as well as liver injury in
HFD-treated mice.
The food intake of mice fed an ND was higher than that of mice fed HFD due to the low energy density of the ND (Fig.1A ). Oral administration of PSPC did not markedly influence the food intake in either ND-fed mice or HFD-fed mice ( Moreover, 20 weeks of HFD significantly elevated obesity-related metabolic parameters in mice, including epididymal adipose tissue masses, liver index, fasting blood glucose, serum insulin, serum TG, serum Chol, serum NEFA, serum LDL-C and HDL-C ( Fig. 2 HFD group) and effectively improved these obesity-related metabolic parameters and liver injuries in HFD-treated mice ( Fig. 2 and 3 ; epididymal adipose tissue: p < 0.001; Liver index: p < 0.001; fasting blood glucose: p < 0.001; serum insulin: p < 0.001; serum TG: p < 0.001; serum Chol: p < 0.001; serum NEFA: p < 0.001; serum LDL-C: p < 0.001; serum HDL-C: p < 0.05; ALT: p < 0.001, versus HFD group). No significant differences in obesity and related metabolic parameters, and liver injuries were found among the HFD+PSPC, PSPC and the control groups. The above results indicated that PSPC effectively suppressed HFD-induced obesity and related metabolic parameters and liver injury.
PSPC ameliorates hepatic steatosis in HFD-treated mice.
A striking accumulation of hepatic lipids was evidenced by a marked increase in hepatic TG, Chol and NEFA levels in HFD-treated mice ( Fig. 4A-C There were no significant differences in hepatic redox status among the HFD + PSPC, PSPC and control groups. These results indicated that PSPC significantly abated oxidative stress in the livers of HFD-treated mice.
PSPC blocks Src activation in HFD-treated mouse livers.
It is well demonstrated that oxidative stress activates Src under various pathological conditions (Pal et al. 2014; Chattopadhyay et al. 2015) , which might promote the development of HFD-induced hepatic steatosis. As shown in Figure 6 , HFD treatment induced the marked activation of Src by enhancing the phosphorylation of Src, as well as its activity, in mouse livers ( A considerable amount of evidence has indicated that oxidative stress is a response to the development of NAFLD (Rinella 2015; Byrne and Targher 2015) . Oxidative stress results from an imbalance between prooxidants and antioxidants, characterised by increased level of ROS, which acts directly on essential biomolecules or indirectly activates redox-sensitive signalling cascades to induce steatosis (Rinella 2015) . In the present study, HFD induced an increase in the levels of ROS and lipid peroxidation and a decline in the reducing potential in mouse livers, suggesting that oxidative stress was involved in the development of HFD-induced hepatic steatosis. Substantial evidence has demonstrated that PSPC has D r a f t 18 stronger antioxidant activity than many other plant pigments (Chao et al. 2014 ). Our previous findings also suggest that PSPC attenuates HFD-induced hepatic insulin resistance via blocking oxidative stress (Zhang et al. 2013 ). This study showed that PSPC attenuated oxidative stress in the livers of HFD-treated mice by reducing ROS and lipid peroxidation levels and increasing GSH content and antioxidant enzyme activity. Our results consistently suggested that PSPC improved HFD-induced hepatic steatosis by abating oxidative stress.
Once activated, Src participates in many pathophysiological processes, including autophagy (Pal et al. 2014 ) and inflammation (Byeon et al. 2012) . suggested that C/EBPβ overexpression augments the mRNA and protein expression of CD36, which leads to diet-induced hepatic steatosis (Qiao et al. 2008; Pisonero-Vaquero et al. 2015) .
In this study, our data showed that the protein level of CD36 was markedly increased in the livers of HFD-fed mice, indicating that HFD might promote fatty acid uptake to facilitate hepatic steatosis via enhancing C/EBPβ-mediated CD36 expression. Accumulated evidence has demonstrated that decreased expression of CPT1A, a rate-limiting enzyme in fatty acid oxidation, abates the entry of fatty acids into mitochondria for oxidation, which contributes to steatosis (Long and Zierath 2006; Derdak et al. 2013) . Enhanced ACC has been indicated to increase the production of malonyl-CoA to inhibit CPT1A, exacerbating steatosis, and this Consistent with previous reports, our results showed that PSPC inhibited the expression and activation of lipogenic enzymes (ACC and FAS) and a fatty acid transporter (CD36), while increasing the expression of a rate-limiting enzyme in fatty acid oxidation (CPT1A) in the livers of HFD-fed mice. Our findings indicated that PSPC might exhibit its beneficial effects on hepatic steatosis via blocking C/EBPβ signalling, consequently depressing lipogenesis and fatty acid uptake and enhancing fatty acid oxidation. Substantial evidence has indicated that impaired AMPK activation contributes to the development of hepatic steatosis (Castaño et al. 2014; Woods et al. 2017) . AMPK has been established to directly phosphorylate ACC to inactivate it, which abates lipogenesis and facilitates fatty acid oxidation (Fullerton et al. 2013 ). In the present study, our results showed that HFD remarkably restrained AMPK activation in the mouse livers, which was reversed by U0126 treatment. Recently, ERK signalling has been reported to inhibit AMPK activation in some settings, such as insulin resistance (Damm et al. 2012; Hwang et al. 2013 ). Thus, our findings indicated that HFD might suppress AMPK activation via activating ERK signaling in mouse livers. Accumulating evidence has suggested that natural flavonoids improve the features of NAFLD, including steatosis, via activating AMPK (Salomone et al. 2016; Song et al. 2016 Obesity is closely associated with the features of metabolic syndrome, such as steatosis, dyslipidaemia, hyperglycaemia, hypertension, and insulin resistance. Excessive accumulation of adipose tissue aberrantly secretes adipokines and cytokines during obesity, which causes abnormalities of glucose and lipid metabolism in the liver, contributing to the development of NAFLD (Duval du et al. 2010; Plessis et al. 2015) . In obesity, the intestinal mucosal integrity is impaired and the intestinal permeability is increased, which elevate circulating bacterial endotoxins, leading to the development and progression of NAFLD (Brun et al. 2007 ). In the present study, PSPC significantly reduced the body weight and epididymal adipose tissue masses without affecting food intake in HFD-fed mice. Natural flavonoids are reported to improve aberrant release of adipokines/cytokines by adipose tissue and ameliorate obesity-associated intestinal alterations (Liu et al. 2007 ; Suzuki and Hara 2011). Thus, our findings indicated that PSPC might improve the dysregulation of hepatic lipid metabolism by ameliorating obesity-associated aberrant release of adipokines/cytokines and intestinal alterations, although this requires further study.
In conclusion, our data showed that PSPC exhibited a remarkable protective effect against HFD-induced hepatic steatosis, which were associated with inhibiting oxidative stress-mediated Src activation, further blocking the ERK signal pathway and its downstream C/EBPβ signalling and restoring AMPK activation, ultimately suppressing lipogenesis and fatty acid uptake and enhancing fatty acid oxidation. These ameliorative effects of PSPC on hepatic steatosis might be related to its anti-obesity effect. Therefore, this study provides novel mechanistic insights into NAFLD pathogenesis and a theoretical basis for PSPC as a therapeutic agent in NAFLD and diabetes. 181x235mm (600 x 600 DPI)
